17554 Holly Well Ave., Tampa, FL 33598
Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which […]
FDA Tightens Oversight of GLP-1 Ingredients Imports Read More »
Sept. 8, 2025 WW today announced the launch of Weight Watchers for Menopause, a program that is designed to support women through every stage of the menopause journey, from perimenopause to post-menopause. To launch the program, WeightWatchers is partnering with Grammy and Emmy Award-winning and Oscar-nominated actress, producer, entrepreneur, and health advocate Queen Latifah as
Queen Latifah To Pitch New Weight Watchers Menopause Program Read More »
August 11, 2025 The company emerged from its financial reorganization process on June 24, 2025. According to Tara Comonte, CEO of Weight Watchers: “This marks the beginning of an exciting new chapter for the Company, one that’s grounded in stronger financial footing and a clear sense of opportunity. With greater flexibility to invest, we’re accelerating
Weight Watchers Reports Q2 2025 Results Read More »
August 4, 2025 “We are working diligently to transform our business as we look to help more people achieve optimal metabolic health,” said Dan Chard, CEO of Medifast. “We’re focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and
Medifast Reports Q2 Results – Slide Continues Read More »
July 8, 2025 There is no doubt that the number of weight loss (bariatric) surgeries has fallen, due to the competition from the GLP-1 drugs, since 2022. Marketdata (the owner of DietBusinessWatch.com) has estimated that procedure volume has declined 25% since 2022, to 211,000 procedures in 2024, as Americans opted for the new drugs instead.
How Are Weight Loss Surgeons Coping With Less Surgeries? Read More »
June 18, 2025 Following approval of its Plan of Reorganization, WW is on track to exit the court-supervised financial reorganization process as early as next week. “This is a meaningful turning point for WeightWatchers,” said Tara Comonte, CEO of Weight Watchers. “We’ve taken decisive action to significantly strengthen our financial foundation and will emerge with
Weight Watchers Reorganization Plan Confirmed Read More »
May 6, 2025 WW management reported first quarter 2025 results today. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support,
Weight Watchers Reports Q1 Results Read More »
April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to
Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »
April 28, 2025 According to CEO Dan Chard: “This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.” First quarter 2025 revenue decreased 33.8% to $115.7 million from $174.7 million for the
Medifast Reports First Quarter Results – Slide Continues Read More »
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »